{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458269412
<!-- Monoclonal antibody data -->
| type = mab
| mab_type = mab
| source = o
| target = [[CA125]]
<!-- Clinical data -->
| tradename = OvaRex
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status =  
| routes_of_administration =  
<!-- Pharmacokinetic data -->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =  
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 213327-37-8
| ATC_prefix = none
| ATC_suffix =  
| ATC_supplemental =  
| PubChem =  
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D05269
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula =  
| molecular_weight = ca. 150 kg/mol
}}

'''Oregovomab''' (marketed under the trade name '''OvaRex''') is a [[mouse]] [[monoclonal antibody]] it binds to the antigen [[CA125]], a [[carbohydrate]] antigen. It is designed for the treatment of [[ovarian cancer]].<ref>[http://www.ama-assn.org/ama/upload/mm/365/oregovomab.doc Statement On A Nonproprietary Name Adopted By The USAN Council - Oregovomab], ''American Medical Association''.</ref>

This drug was developed by [[AltaRex]] Corp.
==Adverse drug effects==

{{Empty section|date=October 2014}}
==References==
<references/>

{{Monoclonals for tumors}}

[[Category:Monoclonal antibodies for tumors]]
[[Category:Experimental cancer drugs]]


{{monoclonal-antibody-stub}}
{{antineoplastic-drug-stub}}